Cargando…

Development of Monoclonal Antibodies Specific for Glycated Prion Protein

Transmissive spongiform encephalopathies (TSE) are neurodegenerative diseases characterized by depositions of abnormally folded prion protein (PrP(TSE)) in brain. PrP(TSE) is at present the only specific biochemical marker of human and animal TSE. As deposits of PrP(TSE) remain in the body for long...

Descripción completa

Detalles Bibliográficos
Autores principales: Dvorakova, Eva, Prouza, Marek, Janouskova, Olga, Panigaj, Martin, Holada, Karel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259618/
https://www.ncbi.nlm.nih.gov/pubmed/22043908
http://dx.doi.org/10.1080/15287394.2011.618976
_version_ 1782221411318759424
author Dvorakova, Eva
Prouza, Marek
Janouskova, Olga
Panigaj, Martin
Holada, Karel
author_facet Dvorakova, Eva
Prouza, Marek
Janouskova, Olga
Panigaj, Martin
Holada, Karel
author_sort Dvorakova, Eva
collection PubMed
description Transmissive spongiform encephalopathies (TSE) are neurodegenerative diseases characterized by depositions of abnormally folded prion protein (PrP(TSE)) in brain. PrP(TSE) is at present the only specific biochemical marker of human and animal TSE. As deposits of PrP(TSE) remain in the body for long periods, there is substantial chance of them being nonenzymatically modified by glycation. The detection of glycated PrP(TSE) may have potential to serve as a diagnostic marker. Monoclonal antibodies specific for carboxymethyl lysine/arginine-modified prion protein were prepared. Recombinant human prion protein (rhPrP) was bacterially expressed and purified by affinity chromatography. rhPrP was modified by glyoxylic acid that introduces carboxymethyl groups on lysine and arginine residues present within the molecule of the protein. Modified rhPrP (rhPrP-CML) was used for immunization of 6 mice, and 960 hybridoma cells were prepared. Screening of cell supernatants resulted in the selection of four promising clones. One of them (EM-31) strongly reacts with human and mouse recombinant PrP-CML, and three other clones react also with CML in vitro modified human and mouse brain PrP. Besides possible implication in TSE diagnostics, the antibodies may serve as tolls to advance our knowledge regarding the role of glycation in the prion pathophysiology.
format Online
Article
Text
id pubmed-3259618
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-32596182012-01-19 Development of Monoclonal Antibodies Specific for Glycated Prion Protein Dvorakova, Eva Prouza, Marek Janouskova, Olga Panigaj, Martin Holada, Karel J Toxicol Environ Health A Research Article Transmissive spongiform encephalopathies (TSE) are neurodegenerative diseases characterized by depositions of abnormally folded prion protein (PrP(TSE)) in brain. PrP(TSE) is at present the only specific biochemical marker of human and animal TSE. As deposits of PrP(TSE) remain in the body for long periods, there is substantial chance of them being nonenzymatically modified by glycation. The detection of glycated PrP(TSE) may have potential to serve as a diagnostic marker. Monoclonal antibodies specific for carboxymethyl lysine/arginine-modified prion protein were prepared. Recombinant human prion protein (rhPrP) was bacterially expressed and purified by affinity chromatography. rhPrP was modified by glyoxylic acid that introduces carboxymethyl groups on lysine and arginine residues present within the molecule of the protein. Modified rhPrP (rhPrP-CML) was used for immunization of 6 mice, and 960 hybridoma cells were prepared. Screening of cell supernatants resulted in the selection of four promising clones. One of them (EM-31) strongly reacts with human and mouse recombinant PrP-CML, and three other clones react also with CML in vitro modified human and mouse brain PrP. Besides possible implication in TSE diagnostics, the antibodies may serve as tolls to advance our knowledge regarding the role of glycation in the prion pathophysiology. Taylor & Francis 2011-11-01 2011-11 /pmc/articles/PMC3259618/ /pubmed/22043908 http://dx.doi.org/10.1080/15287394.2011.618976 Text en © Taylor & Francis Group, LLC http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf This is an open access article distributed under the Supplemental Terms and Conditions for iOpenAccess articles published in Taylor & Francis journals (http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Dvorakova, Eva
Prouza, Marek
Janouskova, Olga
Panigaj, Martin
Holada, Karel
Development of Monoclonal Antibodies Specific for Glycated Prion Protein
title Development of Monoclonal Antibodies Specific for Glycated Prion Protein
title_full Development of Monoclonal Antibodies Specific for Glycated Prion Protein
title_fullStr Development of Monoclonal Antibodies Specific for Glycated Prion Protein
title_full_unstemmed Development of Monoclonal Antibodies Specific for Glycated Prion Protein
title_short Development of Monoclonal Antibodies Specific for Glycated Prion Protein
title_sort development of monoclonal antibodies specific for glycated prion protein
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259618/
https://www.ncbi.nlm.nih.gov/pubmed/22043908
http://dx.doi.org/10.1080/15287394.2011.618976
work_keys_str_mv AT dvorakovaeva developmentofmonoclonalantibodiesspecificforglycatedprionprotein
AT prouzamarek developmentofmonoclonalantibodiesspecificforglycatedprionprotein
AT janouskovaolga developmentofmonoclonalantibodiesspecificforglycatedprionprotein
AT panigajmartin developmentofmonoclonalantibodiesspecificforglycatedprionprotein
AT holadakarel developmentofmonoclonalantibodiesspecificforglycatedprionprotein